$4.78
-0.1-2.05%
At close: -
$4.97
0.193.99%
After Hours: Apr 22, 6:04 PM EDT
Comments
Loading...
Avalo Therapeutics Analyst Ratings and Price Targets | NASDAQ:AVTX | Benzinga
Avalo Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Avalo Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Stifel
Piper Sandler
BTIG
LUCID CAPITAL MARKETS
1calculated from analyst ratings
Analyst Ratings for Avalo Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | — | Jefferies | Kambiz Yazdi49% | → $23 | Initiates | → Buy | Get Alert |
| 03/25/2025 | Buy Now | — | Stifel | Alex Thompson43% | → $36 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | — | HC Wainwright & Co. | Edward White50% | — | Reiterates | Neutral → Neutral | Get Alert |
| 02/28/2025 | Buy Now | — | Piper Sandler | Yasmeen Rahimi57% | → $48 | Initiates | → Overweight | Get Alert |
| 12/19/2024 | Buy Now | — | BTIG | Julian Harrison40% | → $40 | Initiates | → Buy | Get Alert |
| 12/17/2024 | Buy Now | — | LUCID CAPITAL MARKETS | Dev Prasad 8% | → $24 | Initiates | → Buy | Get Alert |
| 10/24/2024 | Buy Now | — | HC Wainwright & Co. | Edward White50% | — | Initiates | → Neutral | Get Alert |
| 04/16/2024 | Buy Now | — | Oppenheimer | Leland Gershell70% | → $35 | Upgrade | Perform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | — | Oppenheimer | Leland Gershell70% | — | Downgrade | Outperform → Perform | Get Alert |
| 06/27/2023 | Buy Now | — | RBC Capital | Gregory Renza47% | $2160 → $180 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/10/2023 | Buy Now | — | RBC Capital | Gregory Renza47% | $4080 → $2160 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | — | Jefferies | Chris Howerton63% | → $720 | Downgrade | Hold → Underperform | Get Alert |
FAQ
What is the target price for Avalo Therapeutics (AVTX) stock?
The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Jefferies on March 25, 2025. The analyst firm set a price target for $23.00 expecting AVTX to rise to within 12 months (a possible 362.73% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avalo Therapeutics (AVTX)?
The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Jefferies, and Avalo Therapeutics initiated their buy rating.
When was the last upgrade for Avalo Therapeutics (AVTX)?
The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.
When was the last downgrade for Avalo Therapeutics (AVTX)?
The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Avalo Therapeutics (AVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Avalo Therapeutics (AVTX) correct?
While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a initiated with a price target of $0.00 to $23.00. The current price Avalo Therapeutics (AVTX) is trading at is $4.97, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
